Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

Core Insights - Humacyte, Inc. has received dedicated funding from the FY 2026 U.S. Department of Defense Appropriations Act to support the evaluation of biologic vascular repair technologies for military personnel suffering from traumatic vascular injuries [1][2] Company Overview - Humacyte is a biotechnology platform company focused on developing universally implantable, bioengineered human tissues at a commercial scale [1] - The company's product, Symvess®, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration (FDA) [3] Legislative Support - The FY 2026 National Defense Authorization Act emphasizes the integration of FDA-approved breakthrough vascular repair technologies for traumatic extremity arterial injury repair, highlighting the need for human-derived bioengineered vessels in battlefield scenarios [2] - Congress has shown increased support for Humacyte's medical innovations by allocating funds to advance the availability of this technology for service members [2] Product Efficacy - Symvess has been tested in battlefield conditions, specifically in Ukraine, where it was used to treat patients with severe injuries, resulting in a 100% survival rate, zero amputations, and no conduit infections among 16 patients in a retrospective study [4] - Symvess is indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed and autologous vein grafts are not feasible [5] Future Developments - Humacyte is developing additional applications for its acellular tissue engineered vessels (ATEVs), including late-stage clinical trials for arteriovenous access for hemodialysis and peripheral artery disease [13] - The company has received various designations from the FDA, including Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for its products [13]